News | Breast Density | March 26, 2019

Volpara Solutions Expands Relationship With GE Healthcare

GE Healthcare is now a global distributor of VolparaDensity software

Volpara Solutions Expands Relationship With GE Healthcare

March 26, 2019 — Volpara Solutions announced the launch of an expanded agreement enabling the worldwide distribution of its VolparaDensity software by GE Healthcare.

Now installed in more than 35 countries, the VolparaDensity clinical application analyzes mammograms using machine learning to provide radiologists with automated, objective and volumetric breast density assessments. It also provides a breast density category shown to correlate to BI-RADS (Breast Imaging-Reporting and Data System) 4th and 5th Editions. VolparaDensity is CE-marked and cleared by the U.S. Food and Drug Administration (FDA), Health Canada and the Therapeutic Goods Administration (TGA).

Having an objective and validated measure of breast density allows providers to deliver personalized breast care to their patients by easily identifying women with dense breasts. Such women have an increased risk of developing breast cancer and are also at a greater risk of having a cancer go undetected using conventional 2-D and 3-D mammography. Since dense breast tissue and cancer appear white on a mammogram, women with dense breasts may benefit from additional screening such as that delivered by the GE Invenia automated breast ultrasound (ABUS). ABUS has been shown to find small, invasive cancers missed by mammography.

Joseph P. Russo, M.D., section chief of women's imaging at St. Luke's University Health Network in Bethlehem, Pa., said, "There are still certain signs of breast cancer that are best seen on a mammogram, which is why the Invenia ABUS is used in addition to mammography. ABUS screening helps find cancers hiding in dense tissue. Accurate density measurements and quality imaging are very important in breast cancer detection. I encourage women to learn their breast density, understand their risk, and talk to their healthcare providers to get the personalized healthcare they need."

For more information: www.volparasolutions.com, www.gehealthcare.com

Related Content

Graphic courtesy of Pixabay

Graphic courtesy of Pixabay

Feature | Artificial Intelligence | April 22, 2019 | By Greg Freiherr
...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
compressed breast during mammography.
360 Photos | 360 View Photos | April 16, 2019
A 360 view of a simulated breast compression for a...
Radiology Publishes Roadmap for AI in Medical Imaging
News | Artificial Intelligence | April 16, 2019
In August 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Md., to explore the future...